Back to Journals » Therapeutics and Clinical Risk Management » Volume 10

Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies

Authors Patel N, Finianos A, Whitaker K, Aragon-Ching J

Received 27 May 2014

Accepted for publication 1 July 2014

Published 16 August 2014 Volume 2014:10 Pages 651—664

DOI https://doi.org/10.2147/TCRM.S57509

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Nihar K Patel, Antoine Finianos, Kristen D Whitaker, Jeanny B Aragon-Ching

Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC, USA

Abstract: The advent of exponential growth of novel agents tested and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of these drugs as they relate to these patients. This review will provide a synopsis of the treatment landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T, radium, and selected emerging agents are presented. A distinct focus on the utilization of enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and Drug Administration approval, as well as patient-focused perspectives and clinical implications are discussed herein.

Keywords: metastatic castration-resistant prostate cancer, enzalutamide, systemic therapies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]